On July 4, 2017 Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada; "Sumitomo Dainippon Pharma") reported that the Board of Directors of Dainippon Sumitomo Pharma America Holdings, Inc. ("DSPAH"), a holding company in the United States wholly-owned by Sumitomo Dainippon Pharma, decided on July 4, 2017 (US time) that DSPAH will change its name as following (Press release, Dainippon Sumitomo Pharma, JUL 4, 2017, View Source [SID1234519748]). Schedule your 30 min Free 1stOncology Demo! 1. New name
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Sumitomo Dainippon Pharma America, Inc.
(Former name: Dainippon Sumitomo Pharma America Holdings, Inc.)
2. Reason for name change
To unify the brand of Sumitomo Dainippon Pharma group by aligning the subsidiary’s name with the parent Company’s name Sumitomo Dainippon Pharma Co., Ltd.
3. Date of the change July 5, 2017 (US time)
4. Outline of DSPAH Company name Dainippon Sumitomo Pharma America Holdings, Inc. Representative Hiroshi Nomura (Chair) Business description Holding company Address of headquarters Wilmington, Delaware, U.S. Capital US1,000$
Month: July 2017
Somatuline® Autogel® 120 mg receives Japanese approval for a new indication for the treatment of gastro-entero-pancreatic neuroendocrine tumors
On July 3, 2017 Ipsen (Euronext: IPN; ADR: IPSEY) and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, reported that Teijin Pharma has received approval from the Japanese Ministry of Health, Labour and Welfare for Ipsen’s subcutaneous drug Somatuline (lanreotide) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP NET) (Press release, Ipsen, JUL 3, 2017, View Source [SID1234519744]). The drug is approved in Japan for the treatment of acromegaly and pituitary gigantism since 2012. Schedule your 30 min Free 1stOncology Demo! The request for the additional approval was filed in July 2016, based on Ipsen’s investigational, pivotal phase III randomised placebo-controlled trial (CLARINET) in 204 patients with GEP NET conducted in 14 countries, and an open-label single group multicenter Phase II trial (J-001) in 32 patients with NET that Teijin Pharma conducted in Japan. This approval establishes Somatuline as the first drug available in Japan for the treatment of pancreatic NET.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Harout Semerjian, Executive Vice-President & President, Specialty Care International & Global Franchises said: "We are pleased that Somatuline is now also available for Japanese patients suffering from gastrointestinal and pancreatic neuroendocrine tumors. In line with our commitment to serve NET patients worldwide, this is a significant step after our partner Teijin launched Somatuline for the treatment of acromegaly and pituitary gigantism in Japan in January 2013."
Akihisa Nabeshima, President of Teijin Pharma said: "It is our great pleasure to now have the capacity to provide a new therapeutic option to NET patients in Japan. We will continue to focus on drug discovery and improve the quality of life of patients by offering them new treatment options to fulfill unmet medical needs."
About Neuroendocrine Tumors
NETs are malignant tumors arising from neuroendocrine cells. Most of the NET tumors present with metastasis and are discovered fortuitously. In some patients, excess hormones secreted from a NET can lead to severe diarrhea, peptic ulcers or hypoglycemia. While incidence rates are relatively rare, at about 3.5 gastrointestinal NET patients and 1.3 pancreatic NET patients per 100,000 people in Japan, the number of patients has been increasing year by year due to disease awareness and better diagnosis[1].
The primary treatment for NETs is removal by surgery, but if this is not possible as the disease is usually disseminated, or if a tumor relapses following surgery, another option is a medical treatment.
About Somatuline
The active substance in Somatuline is lanreotide acetate, a somatostatin analogue that inhibits the secretion of several endocrine, exocrine and paracrine functions. It has been shown to be effective in inhibiting the secretion of GH and certain hormones secreted by the digestive system. Somatuline is marketed as Somatuline Depot within the United States and as Somatuline Autogel in other countries where it has marketing authorization. Somatuline is indicated for the treatment of acromegaly and neuroendocrine tumors in 70 countries.
Immunocore Announces Third Oncology Target Selected in Discovery Collaboration with GlaxoSmithKline
On July 3, 2017 Immunocore Limited, the world’s leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, reported that GlaxoSmithKline (GSK) has selected a third target as part of their ongoing oncology discovery collaboration for multiple novel targets not addressable with antibody-based technologies. Immunocore will generate a novel ImmTAC molecule against the selected target which is relevant in multiple cancers.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This is the third programme to be initiated as part of the discovery collaboration with GSK, announced in 2013. Immunocore is currently working on two other ImmTAC programmes under the agreement. The lead programme is on track for an Investigational New Drug (IND) this year with potential application in Non-Small Cell Lung Cancer (NSCLC), bladder cancer, synovial sarcoma, melanoma and ovarian cancer.
Dr Bent Jakobsen, Chief Scientific Officer at Immunocore, commented: "The initiation of this new programme adds to a growing body of evidence that our ImmTAC technology has real potential to generate novel, potent drug candidates against disease targets which are difficult to address with other biologic platforms. ImmTAC molecules are relevant across a wide range of cancer types and have the ability to tackle solid ‘cold’, low mutation rate tumours – the majority of tumours which are difficult for other immuno-oncology drugs to address. We look forward to beginning work on this additional programme with GSK in oncology."
Dr Axel Hoos, Senior Vice President Therapeutic Area Head Oncology R&D Head, Immuno-Oncology at GSK, added: "We are pleased with the progress made in our ongoing collaboration with Immunocore and are excited to add a yet another target to the programme. ImmTAC molecules have great potential among the third generation of immuno-oncology agents and we look forward to seeing this promising program progress."